A Phase 3 interventional study of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT) and 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine in Pneumococcal Infections, Streptococcal Infections and Bacterial Infections, sponsored by CanSino Biologics Inc.. Completed at 1 site in China. Open to participants aged 6 Weeks and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-02.
Sponsored by CanSino Biologics Inc. · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Pneumococcal Infections with a site in China — 6 open to participants now, 9 under way, 4 of them phase 3. Pneumococcal Infections · China.
Among the 36 studies in Pneumococcal Infections with a site in China, this one has the largest enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2021, is one of 9 in phase 3, and was the 11th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →6 of the 36 studies in Pneumococcal Infections with a site in China are open now. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
CanSino Biologics Inc. · Sites in China
Ages 6 wk+ · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 42 days–5 yrs · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 42 days–23 mo · Healthy volunteers
Sinovac Life Sciences Co., Ltd. · Sites in China
Ages 6 wk–5 yrs · Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 6 Weeks and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 5 · Phase 3 9 · Phase 4 6
First in 2007; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,420 is above the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 480 across the 33 interventional studies, 3,641 across the 3 observational. Of the 26 that completed or were terminated, 4 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 36 have an industry lead sponsor. The 10 most frequent:
CanSino Biologics Inc. is the lead sponsor of 41 studies on the registry; 6 are open to participants now.
CanSino Biologics Inc. has 5 studies filed under Pneumococcal Infections — fewer than ten, so there is no comparison to draw.
2 of the studies in Pneumococcal Infections with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600983CanSino Biologics Inc.Clinical Trial of the 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) | 2026-11-24 |
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 36 studies in Pneumococcal Infections with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Streptococcus pneumoniae is a major cause of morbidity and mortality in children worldwide, resulting in up to 1 million pediatric deaths every year.Since the licensure of PCV7 and PCV13,the reported overall decline in invasive pneumococcal disease in hospitalized children younger than 5 years several years is approximately 60% in Western countries.This is a single center,blind, randomized, positive-controlled clinical trial.The purpose of this study is to preliminary evaluate the safety of PCV13i vaccine in subjects at age of 7 months and above,and to investigate the safety and immunogenicity of PCV13i vaccine at age of 2 and 3 months,compared to PCV13.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received four doses of PCV13i at 2 months of age (At least 6 weeks old)
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received four doses of PCV13 at 2 months of age (At least 6 weeks old)
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received four doses of PCV13i at 3 months of age
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subject received three doses of PCV13i at 7 to 11 months of age
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subject received three doses of PCV13 at 7 to 11 months of age
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received two doses of PCV13i at 12 to 23 months of age
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received two doses of PCV13 at 12 to 23 months of age
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
Subjects received one dose of PCV13i at 2 to 5 years old.
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine(CRM197,TT)
Subjects received one dose of PCV13 at 2 to 5 years old.
Biological: 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine
0.5mL,Intramuscular
Also known as: PCV13i
0.5mL,Intramuscular
Also known as: Prevnar
Safety of PCV13i in preventing pneumococcal infections
Occurance of adverse reactions in all subjects
Time frame: Within 7 days post each vaccination
Safety of PCV13i in preventing pneumococcal infections
Occurance of adverse reactions in all subjects
Time frame: Within 30 days post each vaccination
Immunogenicity of PCV13i in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)
Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml
Time frame: 30 days post three doses
Immunogenicity of PCV13i in subjects of 7 to 11 months old (Arm 4A-4B)
Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml
Time frame: 30 days post three doses
Immunogenicity of PCV13i in subjects of 12 months to 5 years old (Arm 5A, 5B, 6A, 6B)
Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml
Time frame: 30 days post last dose of vaccination
Immunogenicity of PCV13i in subjects of age 50 years old and above (Arm 6A, 6B, 7A, 7B)
Serotype-specific seropositivity rates of Immunoglobulin G GMC concentrations above 0.35ug/ml
Time frame: 30 days post vaccination
Immuogenicity in terms of GMT in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)
GMT of serotype-specific OPA antibody with the titer of ≥1:8 ratio
Time frame: 30 days post three doses
Immunogenicity in terms of IgG concentration in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)
Serotype-specific Immunoglobulin G with a concentration of ≥1.0μg/ml
Time frame: 30 days post three doses
Safety of PCV13i in terms of in subjects of 2 months (at least 6 weeks) old (Arm 1A-1B)
Occurance of SAE in subjects of this age group
Time frame: 6 months post one to three doses of vaccination
Immuogenicity in terms of GMT in subjects of 7 to 11 months old (Arm 3A-3B)
GMT of serotype-specific OPA antibody with the titer of ≥1:8 ratio
Time frame: 30 days post two doses
Immuogenicity in terms of GMT in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B)
GMT of serotype-specific OPA antibody with the titer of ≥1:8 ratio
Time frame: 30 days post last dose of vaccination
Immunogenicity in terms of IgG concentration in subjects of 7 to 11 months old (Arm 3A-3B)
Serotype-specific Immunoglobulin G with a concentration of ≥1.0μg/ml
Time frame: 30 days post two doses
Immunogenicity in terms of IgG concentration in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B)
Serotype-specific Immunoglobulin G with a concentration of ≥1.0μg/ml
Time frame: 30 days post last dose of vaccination
Safety of PCV13i in terms of SAE in subjects of 7 to 11 months old (Arm 3A-3B)
Occurance of SAE in subjects of this age group
Time frame: 6 months post two doses
Safety of PCV13i in terms of SAE in subjects of 12 months to 5 years old (Arm 4A, 4B, 5A, 5B)
Occurance of SAE in subjects of this age group
Time frame: 6 months post last dose of vaccination
Ran from Apr 2021 to primary completion in Mar 2022, 11 months.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 11 months is close to that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.